PROJECT STAGE
Therapeutic area
Cardiovascular disease; osteolytic diseases /oncology
Background info
Indication
Advantages
Intellectual property
Owner/lead
Project Aim
First-in-class anti-netrin-1 humanised antibody for the treatment of atherosclerosis
Advantage
An anti-netrin-1 therapeutic offers the potential to reverse atherosclerosis with an additive benefit to cholesterol reduction interventions
Target Class
Dependence Receptor Ligand
Modality
Antibody
Current Status
Hit to Lead. Antibody characterisation and selection prior to humanisation
Intellectual Property
Initial filings with the opportunity to create a protective IPR portfolio
Offering
Licence or shared risk collaboration